The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: AUTHORS’ INFORMATION: RR serves as chair of the Advanced Bleeding Care in Trauma (ABC-T) European Medical Education Initiative. DRS serves as co-chair of the ABC-T European Medical Education Initiative. BB is a member of the ABC-T European Medical Education Initiative faculty. VC is a member of the ABC-T European Medical Education Initiative faculty. JD represented the European Society of Intensive Care Medicine (ESICM) on the ABC-T Task Force. DF represented the European Society of Anaesthesiology (ESA) on the ABC-T Task Force. MM represented the European Shock Society (ESS) on the ABC-T Task Force. GN is a member of the ABC-T European Medical Education Initiative faculty. BJH is a member of the ABC-T European Medical Education Initiative faculty. RK represented the European Society of Trauma and Emergency Surgery (ESTES) on the ABC-T Task Force. LR represented the European Society for Emergency Medicine (EuSEM) on the ABC-T Task Force. CMS represented the Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (NATA) on the ABC-T Task Force. JLV is a member of the ABC-T European Medical Education Initiative faculty. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: In the past 5 years, DRS’s academic department has received grant support from the Swiss National Science Foundation, Berne, Switzerland, the Ministry of Health (Gesundheitsdirektion) of the Canton of Zurich, Switzerland for Highly Specialized Medicine, the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, CSL Behring, Berne, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland. DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland. DRS received honoraria or travel support for consulting or lecturing from: Danube University of Krems, Austria, US Department of Defense, Washington, USA, European Society of Anesthesiology, Brussels, BE, Korea, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Baxter AG, Volketswil, Switzerland, Baxter S.p.A., Roma, Italy, Bayer AG, Zürich, Switzerland, Bayer Pharma AG, Berlin, Germany, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Curacyte AG, Munich, Germany, Daiichi Sankyo AG, Thalwil, Switzerland, GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, Octapharma AG, Lachen, Switzerland, Organon AG, Pfäffikon/SZ, Switzerland, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Photonics Healthcare B.V., Utrecht, Netherlands, Roche Diagnostics International Ltd., Reinach, Switzerland, Roche Pharma AG, Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany Schering-Plough International, Inc., Kenilworth, New Jersey, USA, Tem International GmbH, Munich, Germany, Verum Diagnostica GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Vienna, Austria and Villars-sur-Glâne, Switzerland, Vifor (International) AG, St. Gallen. BB has no competing interests to declare. In the past 5 years, VC has received honoraria for consulting or lecturing from CSL Behring, AbbVie, BBraun, Bard. VC reports research grant funding from the Czech Health Research Council, Czech Republic, and the Charles University Faculty of Medicine in Hradec Kralove, Czech Republic. VC has received institutional support from the Charles University Faculty of Medicine in Hradec Kralove, Czech Republic, the University Hospital Hradec Kralove, Czech Republic and Masaryk Hospital Usti nad Labem, Czech Republic. In the past 5 years, JD has received honoraria for lecturing from LFB Biomédicaments. In the past 5 years, DF has received honoraria for lecturing from the following companies and organisations: Romanian Society of Cardiology, MedLife Health System and Danube University of Krems, Austria. DF has received institutional support from Vifor Pharma, Siramed SRL and Synttergy Consult SRL. In the past 5 years, BJH has received research grant funding from CSL Behring. In the past 5 years, RK has received honoraria for lecturing from CSL Behring. In the past 5 years, MM has received honoraria for consulting or lecturing from Astra Zeneca, Bayer, Biotest, CSL Behring, IL Werfen/TEM International, LFB Biomedicaments France and has received research grant funding from CSL Behring. In the past 5 years, GN has received honoraria for lecturing from CSL Behring. LR has no competing interests to declare. In the past 5 years, CMS has received honoraria for consulting or lecturing from Aspen, Daiichi-Sankyo, Medtronic, Roche, BMS, Pfizer, Bayer, Stago, Siemens, Octapharma, LFB Biomédicaments and has received research grant funding from Haemonetics. JLV has no competing interests to declare. In the past 5 years, RR has received honoraria for consulting or lecturing from CSL Behring, Boehringer Ingelheim and Fresenius. In fields related to this work RR or his co-workers received research grant funding from DFG, Bayer, Biotest, Boehringer Ingelheim, CSL Behring, Novo Nordisk and Nycomed. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 6. J Orthop Trauma. 2016 Oct;30 Suppl 3:S2-S6. doi: 10.1097/BOT.0000000000000670. Resuscitation and Treatment of Shock. Beltran MJ(1), Becker TE, Hurley RK, Gurney JM, Hayda RA. Author information: (1)*Department of Orthopaedic Surgery, San Antonio Military Medical Center, San Antonio, TX; †Department of Surgery, Trauma and Critical Care, San Antonio Military Medical Center, San Antonio, TX; ‡United States Army Institute of Surgical Research; and §Department of Orthopaedic Surgery, Brown University, Providence, RI. Hemorrhage continues to be the most common cause of death among service members wounded in combat. Injuries that were previously nonsurvivable in previous wars are now routinely seen by combat surgeons in forward surgical units, the result of improvements in body armor, the universal use of field tourniquets to control extremity hemorrhage at the point of injury, and rapid air evacuation strategies. Combat orthopaedic surgeons remain a vital aspect of the forward surgical unit, tasked with assisting general surgical colleagues in the resuscitation of patients in hemorrhagic shock while also addressing traumatic amputations, open and closed long bone fractures, and mechanically unstable pelvic trauma. Future military and civilian trauma research endeavors will seek to identify how the advances made in the past 15 years will translate toward the emerging battlefield of the future, one where forward surgical units must be lighter, smaller, and more mobile to address the changing scope of military combat operations. DOI: 10.1097/BOT.0000000000000670